Familiar barriers still unresolved-a perspective on the Zika virus outbreak research response

Imagem de Miniatura
Arquivos
art_KOOPMANS_Familiar_barriers_still_unresolveda_perspective_on_the_Zika_2019.PDF (305.2 KB)
Citações na Scopus
19
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCI LTD
Autores
KOOPMANS, Marion
LAMBALLERIE, Xavier de
JAENISCH, Thomas
ROSENBERGER, Kerstin D.
MORALES, Ivonne
MARQUES, Ernesto T. A.
VIANA, Isabelle F. T.
BRASIL, Patricia
RABELLO, Renata
Citação
LANCET INFECTIOUS DISEASES, v.19, n.2, p.E59-E62, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Research is an important component of an effective response to the increasing frequency of widespread infectious disease outbreaks. In turn, the ability to do such studies relies on willingness of partners in different regions to collaborate and the capacity to mount a rapid research response. The EU-funded ZIKAlliance Consortium has initiated a multicountry epidemiological, clinical, and laboratory research agenda to determine the incidence, risk factors, and outcomes of Zika virus infection in pregnant women and their children. We reviewed the timeline of patient cohort initiation in relation to the Zika virus epidemic and mapped key events regarding funding, regulatory approvals, and site preparation during this timeline. We then assessed barriers and delays that the international research team experienced through a systematic telephone interview. We have identified three major bottlenecks in the implementation of a swift response: the absence of a timeline for the funding process, delays in regulatory and ethical approval, and the challenging logistics of laboratory support, including diagnostics. These bottlenecks illustrate the clear and urgent need for implementing a strong and permanent global emerging infectious diseases research capacity that has structured funding, enables long-term partnerships, and develops basic clinical and laboratorial research and a response infrastructure that is ready to deploy.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/31161
Referências
  1. Alirol E, 2017, BMC MED ETHICS, V18, DOI 10.1186/s12910-017-0201-1
  2. Braga JU, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179725
  3. Brasil. Ministerio da Saude, 2015, B EPIDEMIOL, V46, P1
  4. Charrel R, 2017, J CLIN MICROBIOL, V55, P3219, DOI 10.1128/JCM.00987-17
  5. de Oliveira WK, 2017, LANCET, V390, P861, DOI 10.1016/S0140-6736(17)31368-5
  6. Granger D, 2017, J CLIN MICROBIOL, V55, P2127, DOI [10.1128/jcm.00580-17, 10.1128/JCM.00580-17]
  7. Heymann DL, 2016, LANCET, V387, P719, DOI 10.1016/S0140-6736(16)00320-2
  8. Jaenisch T, 2017, B WORLD HEALTH ORGAN, V95, P191, DOI [10.2471/13LT.16.178608, 10.2471/BLT.16.178608]
  9. Jaenisch T, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1440-3
  10. Lee WT, 2017, J CLIN MICROBIOL, V22, P56
  11. Paules CI, 2017, ANN INTERN MED, V167, P805, DOI 10.7326/M17-2496
  12. Perkins MD, 2017, LANCET, V390, P2111, DOI 10.1016/S0140-6736(17)31224-2
  13. Reusken CB, 2018, CLIN MICROBIOL INFEC, V24, P221, DOI 10.1016/j.cmi.2017.12.010
  14. Reveiz L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180220
  15. Ribeiro CD, 2018, SCIENCE, V362, P404, DOI 10.1126/science.aau5229
  16. Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
  17. Van Kerkhove MD, 2016, LANCET GLOB HEALTH, V4, pE911, DOI 10.1016/S2214-109X(16)30255-8
  18. Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/49
Artigos e Materiais de Revistas Científicas - ODS/03